RHEACELL GmbH und Co. KG
19.12.2024 - 11:43
Heidelberg, Germany (ots) - - EMA approves blinded, multi-centric Phase-3 trial (NCT06489028) to investigate the safety and efficacy of allo-APZ2-CVU in patients with CVU - Decision follows FDA approval and is based on positive results from ...
To the press release of RHEACELL GmbH und Co. KG24.09.2024 - 12:25
Heidelberg, Germany (ots) - - FDA approved blinded, multi-centric Phase-3 trial (NCT06489028) to investigate the safety and efficacy of allo-APZ2-CVU in patients with CVU - The study will be conducted at more than 100 sites and is expected to enroll ...
To the press release of RHEACELL GmbH und Co. KG28.02.2024 - 15:00
Heidelberg (ots) - On February 29, 2024, Rare Disease Day will take place worldwide to raise awareness for rare diseases. Only 5% of the approximately 6,000 to 10,000 known rare diseases are currently treatable. The research and development of ...
To the press release of RHEACELL GmbH und Co. KG27.06.2023 - 11:23
Heidelberg (ots) - Stem cell therapy for "butterfly disease" Following positive phase IIa study results, the biopharmaceutical company RHEACELL starts a multi-centre, global phase III study for the clinical testing of its stem cell therapeutic based ...
To the press release of RHEACELL GmbH und Co. KG09.11.2022 - 10:39
Heidelberg (ots) - The biopharmaceutical company RHEACELL, which specializes in stem cells, was honored on October 24 by the organization 'Dystrophic Epidermolysis Bullosa Research Association of America' (debra) with the ‘Partners in Progress ...
To the press release of RHEACELL GmbH und Co. KG 
